查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1608221

路易氏體失智症治療藥物市場：按藥物類型、分銷管道、應用分類 - 全球預測 2025-2030

Lewy Body Dementia Treatment Market by Drug Type (Antidepressants, Antipsychotic Drugs, Benzodiazepine), Distribution Channel (Online Pharmacies, Retail Pharmacies), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

路易氏體失智症藥物市場2023年估值為61.2億美元，預計到2024年將達到66億美元，複合年成長率為8.54%，到2030年將達到108.7億美元。

路易氏體失智症(LBD) 的治療包括多種治療策略來控制這種進行性腦部疾病的症狀，其特徵是會出現影響認知表現、運動和情緒的異常蛋白質沉積。隨著人口老化，對有效 LBD 治療的需求不斷增加，需要乙醯膽鹼酯酶抑制劑和抗精神病藥物等針對性的方法。這些治療方法主要應用於醫療機構，例如醫院和專門的失智症護理機構，以滿足 LBD 患者的神經和精神需求。從市場角度來看，醫療保健專業人員和看護者對 LBD 的認知不斷提高，推動了對更有效、更全面的治療方案的需求。關鍵的成長要素包括神經退化性疾病研究的進展、藥物研發投資的增加以及政府對失智症護理舉措的津貼增加。潛在的商機在於開發副作用較少的新藥、根據個人基因特徵量身定做的個人化醫療方法，以及用於症狀管理的穿戴式裝置等技術創新。然而，市場開拓面臨藥物開發成本高、監管障礙高、LBD診斷複雜等限制，常導致誤診和延誤治療。公司可以透過專注於將人工智慧融入早期診斷、增強病患監測系統以及探索聯合治療的潛力來進行創新。提供遠距離診斷和遠端系統管理的遠端醫療解決方案的潛力也越來越大，可以顯著提高患者和看護者的參與度。隨著市場的發展，由於提供創新解決方案的新進入者的湧入，競爭可能會加劇。儘管有這些挑戰，公司可以透過策略聯盟獲得競爭優勢，專注於未滿足的臨床需求，並保持敏捷的研發方法，以幫助管理 LBD 帶來重大突破。

主要市場統計
基準年[2023] 61.2億美元
預計年份 [2024] 66億美元
預測年份 [2030] 108.7億美元
複合年成長率（%） 8.54%

市場動態：快速發展的路易氏體失智症治療市場的關鍵市場洞察

路易氏體失智症治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 路易氏體失智症盛行率增加且缺乏相關藥物
    • 政府努力提高人們對路易氏體失智症的意識提升
    • 路易氏體失智症治療藥物優惠報銷規定
  • 市場限制因素
    • 與長期照護需求相關的高治療費用
  • 市場機會
    • 路易氏體失智症治療的臨床試驗迅速增加
    • 各國醫療保健設施的增加
  • 市場挑戰
    • 藥物可能產生的副作用

波特的五力：駕馭路易氏體失智症藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對路易氏體失智症治療藥物市場的影響

外部宏觀環境因素在塑造路易氏體失智症治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解路易氏體失智症治療藥物市場的競爭狀況

對路易氏體失智症治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 路易氏體失智症治療藥物市場中的定位矩陣供應商績效評估

FPNV 定位矩陣是評估路易氏體失智症治療藥物市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪路易氏體失智症治療藥物市場的成功之路

對路易氏體失智症治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 缺乏與路易氏體失智症盛行率增加相關的藥物
      • 政府努力提高人們對路易氏體失智症的認知
      • 路易氏體失智症治療的有利報銷規則
    • 抑制因素
      • 治療費用高，需長期護理
    • 機會
      • 路易氏體失智症治療藥物的臨床試驗數量正在迅速增加
      • 各國醫療保健設施的增加
    • 任務
      • 藥物可能產生的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類型分類的路易氏體失智症治療市場

  • 抗憂鬱症
  • 抗精神病藥
  • 苯二氮平類
  • Carbidopa-Levodopa
  • 膽鹼酯酶抑制劑
    • 多奈哌齊
    • Galantamine
    • Rivastigmine
  • Modafinil

第7章路易氏體失智症治療藥物市場：按分銷管道

  • 網路藥房
  • 零售藥房

第8章路易氏體失智症治療藥物市場：依應用分類

  • 阿茲海默症
  • 失智
  • 帕金森氏症

第9章北美和南美路易氏體失智症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區路易氏體失智症治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲路易氏體失智症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Axovant Sciences Ltd.
  • Bausch Health Companies Inc.
  • Bayer AG
  • BioArctic AB
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Immungenetics AG
  • Jazz Pharmaceuticals, Inc
  • Mallinckrodt Pharmaceuticals
  • Novartis AG
  • Noven Pharmaceuticals, Inc
  • Pfizer Inc
  • Sumitomo Dainippon Pharma Co., Ltd
  • Takeda Pharmaceutical Company Ltd.
Product Code: MRR-AE3D5CE2576E

The Lewy Body Dementia Treatment Market was valued at USD 6.12 billion in 2023, expected to reach USD 6.60 billion in 2024, and is projected to grow at a CAGR of 8.54%, to USD 10.87 billion by 2030.

Lewy Body Dementia (LBD) treatment encompasses various therapeutic strategies to manage symptoms of this progressive brain disorder, characterized by abnormal protein deposits affecting cognitive abilities, movement, and mood. The necessity for effective LBD treatments is growing as the aging population increases, necessitating targeted approaches like acetylcholinesterase inhibitors and antipsychotics. These treatments are primarily applied in healthcare settings, including hospitals and specialized dementia care facilities, catering to LBD patients' neurological and psychiatric needs. From a market perspective, the growing awareness of LBD among healthcare professionals and caregivers drives demand for more effective and inclusive therapeutic options. Key growth factors include advances in neurodegenerative disease research, heightened investment in pharmaceutical R&D, and increasing government funding in dementia care initiatives. Potential opportunities lie in developing novel drugs with fewer side effects, personalized medicine approaches tailored to individual genetic profiles, and technological innovations like wearable devices for symptom management. However, the market faces limitations such as the high cost of drug development, significant regulatory hurdles, and the complexity of diagnosing LBD, often leading to misdiagnosis or delayed treatment. Companies can innovate by focusing on integrating artificial intelligence in early diagnosis, enhancing patient monitoring systems, and exploring the potential of combination therapies. There's also a growing scope for telemedicine solutions providing remote diagnosis and management, which can significantly enhance patient and caregiver engagement. As the market evolves, the competition may intensify with an influx of new entrants offering innovative solutions. Despite these challenges, businesses can gain competitive advantages through strategic collaborations, focusing on unmet clinical needs, and maintaining an agile approach to research and development, which can lead to significant breakthroughs in managing LBD.

KEY MARKET STATISTICS
Base Year [2023] USD 6.12 billion
Estimated Year [2024] USD 6.60 billion
Forecast Year [2030] USD 10.87 billion
CAGR (%) 8.54%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lewy Body Dementia Treatment Market

The Lewy Body Dementia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of lewy body dementia and absence of concerned drug
    • Government initiatives for creating awareness about lewy body dementia
    • Favorable reimbursement regulations pertaining to lewy body dementia treatment
  • Market Restraints
    • High treatment cost along with need of long term care
  • Market Opportunities
    • Burgeoning number of performed clinical trials for lewy body dementia treatment
    • Growing healthcare facilities in countries
  • Market Challenges
    • Possible adverse effects of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Lewy Body Dementia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lewy Body Dementia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lewy Body Dementia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lewy Body Dementia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lewy Body Dementia Treatment Market

A detailed market share analysis in the Lewy Body Dementia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lewy Body Dementia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lewy Body Dementia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lewy Body Dementia Treatment Market

A strategic analysis of the Lewy Body Dementia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lewy Body Dementia Treatment Market, highlighting leading vendors and their innovative profiles. These include Axovant Sciences Ltd., Bausch Health Companies Inc., Bayer AG, BioArctic AB, Eisai Co., Ltd., Eli Lilly and Company, Immungenetics AG, Jazz Pharmaceuticals, Inc, Mallinckrodt Pharmaceuticals, Novartis AG, Noven Pharmaceuticals, Inc, Pfizer Inc, Sumitomo Dainippon Pharma Co., Ltd, and Takeda Pharmaceutical Company Ltd..

Market Segmentation & Coverage

This research report categorizes the Lewy Body Dementia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Antidepressants, Antipsychotic Drugs, Benzodiazepine, Carbidopa-Levodopa, Cholinesterase Inhibitors, and Modafinil. The Cholinesterase Inhibitors is further studied across Donepezil, Galantamine, and Rivastigmine.
  • Based on Distribution Channel, market is studied across Online Pharmacies and Retail Pharmacies.
  • Based on Application, market is studied across Alzheimer's Disease, Dementia, and Parkinson's Disease.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of lewy body dementia and absence of concerned drug
      • 5.1.1.2. Government initiatives for creating awareness about lewy body dementia
      • 5.1.1.3. Favorable reimbursement regulations pertaining to lewy body dementia treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment cost along with need of long term care
    • 5.1.3. Opportunities
      • 5.1.3.1. Burgeoning number of performed clinical trials for lewy body dementia treatment
      • 5.1.3.2. Growing healthcare facilities in countries
    • 5.1.4. Challenges
      • 5.1.4.1. Possible adverse effects of drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lewy Body Dementia Treatment Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antidepressants
  • 6.3. Antipsychotic Drugs
  • 6.4. Benzodiazepine
  • 6.5. Carbidopa-Levodopa
  • 6.6. Cholinesterase Inhibitors
    • 6.6.1. Donepezil
    • 6.6.2. Galantamine
    • 6.6.3. Rivastigmine
  • 6.7. Modafinil

7. Lewy Body Dementia Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Online Pharmacies
  • 7.3. Retail Pharmacies

8. Lewy Body Dementia Treatment Market, by Application

  • 8.1. Introduction
  • 8.2. Alzheimer's Disease
  • 8.3. Dementia
  • 8.4. Parkinson's Disease

9. Americas Lewy Body Dementia Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Lewy Body Dementia Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Lewy Body Dementia Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Axovant Sciences Ltd.
  • 2. Bausch Health Companies Inc.
  • 3. Bayer AG
  • 4. BioArctic AB
  • 5. Eisai Co., Ltd.
  • 6. Eli Lilly and Company
  • 7. Immungenetics AG
  • 8. Jazz Pharmaceuticals, Inc
  • 9. Mallinckrodt Pharmaceuticals
  • 10. Novartis AG
  • 11. Noven Pharmaceuticals, Inc
  • 12. Pfizer Inc
  • 13. Sumitomo Dainippon Pharma Co., Ltd
  • 14. Takeda Pharmaceutical Company Ltd.

LIST OF FIGURES

  • FIGURE 1. LEWY BODY DEMENTIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. LEWY BODY DEMENTIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. LEWY BODY DEMENTIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. LEWY BODY DEMENTIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LEWY BODY DEMENTIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LEWY BODY DEMENTIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CARBIDOPA-LEVODOPA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY MODAFINIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. LEWY BODY DEMENTIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. LEWY BODY DEMENTIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023